Last reviewed · How we verify
SSGJ-705
At a glance
| Generic name | SSGJ-705 |
|---|---|
| Sponsor | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors (PHASE2)
- A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SSGJ-705 Monotherapy in Patients with Advanced Malignant Tumors (PHASE1)
- A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Potential Anti-tumor Effects of SSGJ-705 in Patients With Advanced or Metastatic HER2-expressing Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SSGJ-705 CI brief — competitive landscape report
- SSGJ-705 updates RSS · CI watch RSS
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. portfolio CI